NRSN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeuroSense Therapeutics Ltd (NRSN) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has weak financial performance, and no proprietary trading signals are present. While the analyst rating is positive with a long-term price target of $3, the current technical indicators and financials do not support an immediate buy decision.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 49.548, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 0.713, with resistance at 0.74 and support at 0.686. Overall, the technical indicators suggest a lack of strong upward momentum.
Roth Capital initiated coverage with a Buy rating and a $3 price target, citing the potential of PrimeC to generate significant revenue by 2038.
No recent news or significant trading trends from hedge funds or insiders. Financial performance is weak, with a 100% drop in net income and a 40.54% decline in EPS YoY for Q4 2024.
In Q4 2024, revenue remained at 0 with no growth. Net income dropped to 0 (-100% YoY), and EPS declined to -0.44 (-40.54% YoY). Gross margin also remained at 0, showing no improvement.
Roth Capital analyst Boobalan Pachaiyappan initiated coverage with a Buy rating and a $3 price target. The firm is optimistic about PrimeC's potential to address amyotrophic lateral sclerosis and achieve significant revenue by 2038.
